PRLD vs. ZYME, ZNTL, IRON, PRAX, EOLS, ETNB, NRIX, AUPH, NUVB, and COGT
Should you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Zymeworks (ZYME), Zentalis Pharmaceuticals (ZNTL), Disc Medicine (IRON), Praxis Precision Medicines (PRAX), Evolus (EOLS), 89bio (ETNB), Nurix Therapeutics (NRIX), Aurinia Pharmaceuticals (AUPH), Nuvation Bio (NUVB), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical preparations" industry.
Zymeworks (NYSE:ZYME) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.
Zymeworks received 261 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 68.42% of users gave Zymeworks an outperform vote while only 48.08% of users gave Prelude Therapeutics an outperform vote.
In the previous week, Zymeworks had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 4 mentions for Zymeworks and 2 mentions for Prelude Therapeutics. Zymeworks' average media sentiment score of 0.30 beat Prelude Therapeutics' score of 0.15 indicating that Prelude Therapeutics is being referred to more favorably in the news media.
Zymeworks has higher revenue and earnings than Prelude Therapeutics. Zymeworks is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.
Zymeworks presently has a consensus target price of $12.67, suggesting a potential upside of 39.65%. Prelude Therapeutics has a consensus target price of $5.25, suggesting a potential upside of 40.00%. Given Zymeworks' higher possible upside, analysts clearly believe Prelude Therapeutics is more favorable than Zymeworks.
Zymeworks has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.
Prelude Therapeutics has a net margin of 0.00% compared to Prelude Therapeutics' net margin of -249.63%. Prelude Therapeutics' return on equity of -28.37% beat Zymeworks' return on equity.
92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 1.2% of Zymeworks shares are owned by insiders. Comparatively, 62.8% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Zymeworks beats Prelude Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Prelude Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prelude Therapeutics Competitors List
Related Companies and Tools
